Predict your next investment

Engitix company logo
HEALTHCARE | Drug Discovery

See what CB Insights has to offer

Founded Year



Series A | Alive

Total Raised


Last Raised

$6.37M | 3 yrs ago

About Engitix

Engitix focused on the development of tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process.

Engitix Headquarter Location

Royal Free Hospital (1st Floor) Rowland Hill Street

London, England, NW32PF,

United Kingdom

Latest Engitix News

Engitix : Therapeutics appoints Dr Mike Burbridge as VP Oncology and Immuno-oncology

May 4, 2021

05/04/2021 | 04:01am EDT Message : *Required fields Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology. Dr Gino Van Heeke, Engitix’s CSO said “We are delighted to have attracted a scientist as high calibre as Mike, who has the experience and expertise to help push forward our internal therapeutic projects as well as our partnered programmes. His extensive knowledge will also be invaluable in supporting the company’s ambitious plans in oncology drug discovery and development.” Dr Burbridge has over 20 years’ experience in oncology drug discovery, translational research, and clinical development. He joins from the Servier Centre for Therapeutic Innovation in Oncology, where most recently he was Programme Director, External Innovation, responsible for overseeing the identification and evaluation of external opportunities for in-licensing and acquisition at discovery, preclinical and clinical stages. His previous roles at Servier included Director of Oncology Translational and Clinical Research and Clinical Project Director. He received his PhD in Pharmacology from the University of Liverpool. Commenting on his appointment, Dr Burbridge said: “I’m eager to leverage my experience to support the progression of Engitix’s programmes and I look forward to working with the talented team to fulfil the company’s ambition to support the development of new therapeutic options for patients with advanced chronic liver diseases and solid tumours.” – END – About Engitix Ltd Engitix is developing a portfolio of programmes in fibrosis and solid tumours using its pioneering human extracellular matrix (ECM) drug discovery platform. The use of more physiologically relevant human in vitro models is transforming our ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. Engitix was founded in 2016 to commercialise cutting-edge research at the Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL). The company is headquartered in Westworks, White City Place, London, UK. For more information, please visit . View source version on © Business Wire 2021

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Engitix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Engitix is included in 4 Expert Collections, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.



5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Medical Devices

7,869 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Engitix Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Engitix Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.